BioMarin Pharmaceutical Balance Sheet Health
Financial Health criteria checks 6/6
BioMarin Pharmaceutical has a total shareholder equity of $5.1B and total debt of $1.1B, which brings its debt-to-equity ratio to 21.4%. Its total assets and total liabilities are $6.9B and $1.8B respectively. BioMarin Pharmaceutical's EBIT is $188.2M making its interest coverage ratio -3.9. It has cash and short-term investments of $1.0B.
Key information
21.4%
Debt to equity ratio
US$1.09b
Debt
Interest coverage ratio | -3.9x |
Cash | US$1.05b |
Equity | US$5.07b |
Total liabilities | US$1.80b |
Total assets | US$6.87b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: BM8's short term assets ($3.0B) exceed its short term liabilities ($1.1B).
Long Term Liabilities: BM8's short term assets ($3.0B) exceed its long term liabilities ($711.0M).
Debt to Equity History and Analysis
Debt Level: BM8's net debt to equity ratio (0.8%) is considered satisfactory.
Reducing Debt: BM8's debt to equity ratio has reduced from 28.4% to 21.4% over the past 5 years.
Debt Coverage: BM8's debt is well covered by operating cash flow (25.8%).
Interest Coverage: BM8 earns more interest than it pays, so coverage of interest payments is not a concern.